Topic: Autoimmune Diseases
One brand-new FDA approval and one trial win for its blood cancer drug Gazyva added up to a double dose of good news for Roche Monday.
Think the success of several megablockbusters such as AbbVie’s Humira means the anti-inflammation market is fully saturated? Think again.
It took a breakthrough designation, orphan drug status, a Refuse to File letter and some extra trials, but Catalyst has won an FDA nod for Firdapse.
Marion Dorsch, Chief Scientific Officer, Blueprint Medicines
The benefits of the upcoming tax overhaul will be so great that AbbVie is planning $2.5 billion in capital projects in the U.S.
Novartis' second-quarter sales and earnings beat Wall Street expectations, but investors are raising a host of concerns about future prospects.